Long-term glucose metabolism disorders in patient with diabetes is often accompanied by dyslipidemia, especially the elevated level of low-density lipoprotein cholesterol (LDL-C). It is an important risk factor for the development of atherosclerotic cardiovascular disease (ASCVD). Recent studies at home and abroad have also found that diabetes can lead to increased levels of proprotein convertase subtilisin/kexintype 9 (PCSK9). In view of the profound influence of PCSK9 overexpression on low density lipoprotein cholesterol level, cardiovascular risk and atherosclerosis, it is of great significance to explore whether hypoglycemic drugs can reduce the level of PCSK9 in the treatment of diabetes. We summarized the results of the study on the effects of various hypoglycemic drugs on circulating PCSK9 concentration in order to provide ideas for the optimal treatment of diabetes.

Long-term glucose metabolism disorders in patient with diabetes is often accompanied by dyslipidemia, especially the elevated level of low-density lipoprotein cholesterol (LDL-C). It is an important risk factor for the development of atherosclerotic cardiovascular disease (ASCVD). Recent studies at home and abroad have also found that diabetes can lead to increased levels of proprotein convertase subtilisin/kexintype 9 (PCSK9). In view of the profound influence of PCSK9 overexpression on low density lipoprotein cholesterol level, cardiovascular risk and atherosclerosis, it is of great significance to explore whether hypoglycemic drugs can reduce the level of PCSK9 in the treatment of diabetes. We summarized the results of the study on the effects of various hypoglycemic drugs on circulating PCSK9 concentration in order to provide ideas for the optimal treatment of diabetes.

As a key regulator of cholesterol homeostasis, the pre protein converting enzyme Bacillus subtilisin/kexin type 9 (PCSK9) can induce the degradation of LDL receptors (LDLR) to regulate circulating low-density lipoprotein cholesterol (LDL-C) levels. Inhibiting the action of PCSK9 can reduce the risk of type I myocardial infarction in individuals with normal blood lipids. The root cause of type I myocardial infarction is myocardial necrosis caused by spontaneous coronary atherosclerotic thrombosis, and in this process, the role of PCSK9 in regulating blood lipids has gone beyond the original scope. Clinically, exploring this area may enhance physicians' understanding of the role of PCSK9 in type I myocardial infarction and provide new ideas for secondary prevention and treatment of type I myocardial infarction.